Published in Infect Immun on April 01, 2005
Role of D-alanylation of Streptococcus gordonii lipoteichoic acid in innate and adaptive immunity. Infect Immun (2007) 0.97
Anti-group A streptococcal vaccine epitope: structure, stability, and its ability to interact with HLA class II molecules. J Biol Chem (2010) 0.92
Primary activation of antigen-specific naive CD4+ and CD8+ T cells following intranasal vaccination with recombinant bacteria. Infect Immun (2008) 0.90
StreptInCor: a candidate vaccine epitope against S. pyogenes infections induces protection in outbred mice. PLoS One (2013) 0.89
In vivo activation of naive CD4+ T cells in nasal mucosa-associated lymphoid tissue following intranasal immunization with recombinant Streptococcus gordonii. Infect Immun (2006) 0.87
Progress in the development of effective vaccines to prevent selected gram-positive bacterial infections. Am J Med Sci (2010) 0.81
Stimulation of human monocytes with the gram-positive vaccine vector Streptococcus gordonii. Clin Vaccine Immunol (2006) 0.80
A novel live vector group A streptococcal emm type 9 vaccine delivered intranasally protects mice against challenge infection with emm type 9 group A streptococci. Clin Vaccine Immunol (2014) 0.75
Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD) Clin Exp Immunol (1995) 4.81
Adhere today, here tomorrow: oral bacterial adherence. J Bacteriol (1993) 3.40
The role of the streptococcus in the pathogenesis of rheumatic fever. Am J Med (1954) 2.72
Streptococcal M protein. Sci Am (1991) 1.98
Vaccination strategies for mucosal immune responses. Clin Microbiol Rev (2001) 1.98
Mucosal and systemic immune responses to a recombinant protein expressed on the surface of the oral commensal bacterium Streptococcus gordonii after oral colonization. Proc Natl Acad Sci U S A (1995) 1.80
Therapy of mucosal candidiasis by expression of an anti-idiotype in human commensal bacteria. Nat Biotechnol (2000) 1.79
Streptococcal pharyngitis in the general population. II. The attack rate of rheumatic fever and acute glomerulonephritis in patients. J Infect Dis (1971) 1.69
Population dynamics of Streptococcus mitis in its natural habitat. Infect Immun (2001) 1.40
Delivery and expression of a heterologous antigen on the surface of streptococci. Infect Immun (1992) 1.32
Clonal diversity of Streptococcus mitis biovar 1 isolates from the oral cavity of human neonates. Clin Diagn Lab Immunol (1996) 1.30
Rheumatic fever following streptococcal vaccination. Report of three cases. JAMA (1969) 1.25
Protective studies with a group A streptococcal M protein vaccine. II. Challange of volenteers after local immunization in the upper respiratory tract. J Infect Dis (1975) 1.20
Protective studies with group A streptococcal M protein vaccine. III. Challenge of volunteers after systemic or intranasal immunization with Type 3 or Type 12 group A Streptococcus. J Infect Dis (1978) 1.16
Immunization with recombinant Streptococcus gordonii expressing tetanus toxin fragment C confers protection from lethal challenge in mice. Vaccine (2001) 1.13
Growth, development, and gene expression in a persistent Streptococcus gordonii biofilm. Infect Immun (2003) 1.09
Host-vector system for integration of recombinant DNA into chromosomes of transformable and nontransformable streptococci. J Bacteriol (1988) 1.09
The microbicide cyanovirin-N expressed on the surface of commensal bacterium Streptococcus gordonii captures HIV-1. AIDS (2002) 1.07
IgA1 proteases of oral streptococci: ecological aspects. Immunol Invest (1989) 1.07
Active release of bound antibody by Streptococcus mutans. Infect Immun (1995) 1.05
Oral colonization and immune responses to Streptococcus gordonii expressing a pertussis toxin S1 fragment in mice. FEMS Microbiol Lett (2002) 1.01
Expression of M6 protein gene of Streptococcus pyogenes in Streptococcus gordonii after chromosomal integration and transcriptional fusion. Res Microbiol (1992) 1.01
Immunogenicity of the B monomer of Escherichia coli heat-labile toxin expressed on the surface of Streptococcus gordonii. Infect Immun (2000) 1.00
Surface expression of a protective recombinant pertussis toxin S1 subunit fragment in Streptococcus gordonii. Infect Immun (1999) 0.98
Establishment of streptococci in the upper respiratory tract: longitudinal changes in the mouth and nasopharynx up to 2 years of age. J Med Microbiol (2002) 0.94
Distribution and isolation frequency of eight streptococcal species in saliva from predentate and dentate children and adults. J Dent Res (1993) 0.93
Expression of functional Porphyromonas gingivalis fimbrillin polypeptide domains on the surface of Streptococcus gordonii. Appl Environ Microbiol (1996) 0.93
Analysis of factors affecting surface expression and immunogenicity of recombinant proteins expressed by gram-positive commensal vectors. Infect Immun (2002) 0.84
Composition of the oral streptococcal flora in healthy children. J Dent (2000) 0.83
Colonization of the murine oral cavity by Streptococcus gordonii. Infect Immun (1994) 0.82
Persistence and spread of the orally-implanted bacterium Streptococcus sanguis between persons. Arch Oral Biol (1986) 0.82
Humoral immunity to commensal oral bacteria: quantitation, specificity and avidity of serum IgG and IgM antibodies reactive with Actinobacillus actinomycetemcomitans in children. Microbiol Immunol (1995) 0.81
In vivo mucosal delivery of bioactive human interleukin 1 receptor antagonist produced by Streptococcus gordonii. BMC Biotechnol (2003) 0.79
Streptococcus gordonii strains resistant to fluorodeoxyuridine contain mutations in the thymidine kinase gene and are deficient in thymidine kinase activity. Antimicrob Agents Chemother (2000) 0.79
Biological consequences of antigen and cytokine co-expression by recombinant Streptococcus gordonii vaccine vectors. Vaccine (2002) 0.77
Prevalence of celiac disease in at-risk and not-at-risk groups in the United States: a large multicenter study. Arch Intern Med (2003) 7.80
A bacteriolytic agent that detects and kills Bacillus anthracis. Nature (2002) 5.63
Genetic diversity among Enterococcus faecalis. PLoS One (2007) 2.32
Safety and immunogenicity of a recombinant multivalent group a streptococcal vaccine in healthy adults: phase 1 trial. JAMA (2004) 2.19
Phage lytic enzyme Cpl-1 as a novel antimicrobial for pneumococcal bacteremia. Infect Immun (2003) 2.06
Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. Antimicrob Agents Chemother (2006) 1.92
Humoral, mucosal, and cellular immune responses to oral Norwalk virus-like particles in volunteers. Clin Immunol (2003) 1.89
Efficacy of the antipoxvirus compound ST-246 for treatment of severe orthopoxvirus infection. Am J Trop Med Hyg (2007) 1.86
Removal of group B streptococci colonizing the vagina and oropharynx of mice with a bacteriophage lytic enzyme. Antimicrob Agents Chemother (2005) 1.79
Systemic use of the endolysin Cpl-1 rescues mice with fatal pneumococcal pneumonia. Crit Care Med (2009) 1.74
The secret life of the anthrax agent Bacillus anthracis: bacteriophage-mediated ecological adaptations. PLoS One (2009) 1.73
Pox proteomics: mass spectrometry analysis and identification of Vaccinia virion proteins. Virol J (2006) 1.69
Identification of a broadly active phage lytic enzyme with lethal activity against antibiotic-resistant Enterococcus faecalis and Enterococcus faecium. J Bacteriol (2004) 1.67
Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine. Am J Trop Med Hyg (2003) 1.65
The vaccinia virus I7L gene product is the core protein proteinase. J Virol (2002) 1.61
Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naïve adults. Hum Vaccin (2009) 1.61
PlyC: a multimeric bacteriophage lysin. Proc Natl Acad Sci U S A (2006) 1.53
Evaluation of orally delivered ST-246 as postexposure prophylactic and antiviral therapeutic in an aerosolized rabbitpox rabbit model. Antiviral Res (2008) 1.50
Synergism between a novel chimeric lysin and oxacillin protects against infection by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother (2010) 1.48
Detailed genomic analysis of the Wbeta and gamma phages infecting Bacillus anthracis: implications for evolution of environmental fitness and antibiotic resistance. J Bacteriol (2006) 1.46
Novel strategy to prevent otitis media caused by colonizing Streptococcus pneumoniae. PLoS Pathog (2007) 1.45
ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification. Antimicrob Agents Chemother (2009) 1.45
Lysins: the arrival of pathogen-directed anti-infectives. J Med Microbiol (2013) 1.43
PCR method to identify Salmonella enterica serovars Typhi, Paratyphi A, and Paratyphi B among Salmonella Isolates from the blood of patients with clinical enteric fever. J Clin Microbiol (2008) 1.40
Identification by PCR of non-typhoidal Salmonella enterica serovars associated with invasive infections among febrile patients in Mali. PLoS Negl Trop Dis (2010) 1.39
Identification and characterization of potent small molecule inhibitor of hemorrhagic fever New World arenaviruses. Antiviral Res (2005) 1.38
Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses. Antimicrob Agents Chemother (2007) 1.38
Deletion in the Shigella enterotoxin genes further attenuates Shigella flexneri 2a bearing guanine auxotrophy in a phase 1 trial of CVD 1204 and CVD 1208. J Infect Dis (2004) 1.31
Novel bacteriophage lysin with broad lytic activity protects against mixed infection by Streptococcus pyogenes and methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother (2013) 1.31
A novel chimeric lysin shows superiority to mupirocin for skin decolonization of methicillin-resistant and -sensitive Staphylococcus aureus strains. Antimicrob Agents Chemother (2010) 1.29
Safety, reactogenicity and immunogenicity of a recombinant protective antigen anthrax vaccine given to healthy adults. Hum Vaccin (2007) 1.26
The in vitro interaction of Streptococcus pyogenes with human pharyngeal cells induces a phage-encoded extracellular DNase. Infect Immun (2002) 1.26
Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor. Antimicrob Agents Chemother (2008) 1.24
Identification of a broad-spectrum arenavirus entry inhibitor. J Virol (2008) 1.23
The 1.6 A crystal structure of the catalytic domain of PlyB, a bacteriophage lysin active against Bacillus anthracis. J Mol Biol (2006) 1.23
Vaccination of BALB/c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge. J Virol (2008) 1.22
First complete genome sequence of two Staphylococcus epidermidis bacteriophages. J Bacteriol (2006) 1.21
Lysogeny of Streptococcus pneumoniae with MM1 phage: improved adherence and other phenotypic changes. Infect Immun (2006) 1.21
Molecular dissection of the vaccinia virus I7L core protein proteinase. J Virol (2003) 1.20
Sortase A localizes to distinct foci on the Streptococcus pyogenes membrane. Proc Natl Acad Sci U S A (2008) 1.20
Safety and immunogenicity of CVD 1208S, a live, oral DeltaguaBA Deltasen Deltaset Shigella flexneri 2a vaccine grown on animal-free media. Hum Vaccin (2007) 1.20
Role of the C-terminal lysine residues of streptococcal surface enolase in Glu- and Lys-plasminogen-binding activities of group A streptococci. Infect Immun (2004) 1.19
Phage lytic enzyme Cpl-1 for antibacterial therapy in experimental pneumococcal meningitis. J Infect Dis (2008) 1.19
In vitro efficacy of ST246 against smallpox and monkeypox. Antimicrob Agents Chemother (2008) 1.19
Activity of the anti-orthopoxvirus compound ST-246 against vaccinia, cowpox and camelpox viruses in cell monolayers and organotypic raft cultures. Antivir Ther (2007) 1.17
Escherichia coli DegP protease cleaves between paired hydrophobic residues in a natural substrate: the PapA pilin. J Bacteriol (2002) 1.16
Phase I evaluation of delta virG Shigella sonnei live, attenuated, oral vaccine strain WRSS1 in healthy adults. Infect Immun (2002) 1.15
Synergistic killing of Streptococcus pneumoniae with the bacteriophage lytic enzyme Cpl-1 and penicillin or gentamicin depends on the level of penicillin resistance. Antimicrob Agents Chemother (2005) 1.15
Isolation of Clostridium perfringens type B in an individual at first clinical presentation of multiple sclerosis provides clues for environmental triggers of the disease. PLoS One (2013) 1.14
A novel secreted endoglycosidase from Enterococcus faecalis with activity on human immunoglobulin G and ribonuclease B. J Biol Chem (2004) 1.12
Group A streptococcal vaccines: paving a path for accelerated development. Vaccine (2013) 1.12
X-ray crystal structure of the streptococcal specific phage lysin PlyC. Proc Natl Acad Sci U S A (2012) 1.11
Mutagenesis of a bacteriophage lytic enzyme PlyGBS significantly increases its antibacterial activity against group B streptococci. Appl Microbiol Biotechnol (2006) 1.10
Combination therapy with lysin CF-301 and antibiotic is superior to antibiotic alone for treating methicillin-resistant Staphylococcus aureus-induced murine bacteremia. J Infect Dis (2013) 1.09
T cell mimicry and epitope specificity of cross-reactive T cell clones from rheumatic heart disease. J Immunol (2005) 1.09
New class of orthopoxvirus antiviral drugs that block viral maturation. J Virol (2004) 1.07
Listeria monocytogenes 10403S HtrA is necessary for resistance to cellular stress and virulence. Infect Immun (2006) 1.07
ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation. Antimicrob Agents Chemother (2009) 1.07
Mucosal vaccine made from live, recombinant Lactococcus lactis protects mice against pharyngeal infection with Streptococcus pyogenes. Infect Immun (2004) 1.07
Effective antiviral treatment of systemic orthopoxvirus disease: ST-246 treatment of prairie dogs infected with monkeypox virus. J Virol (2011) 1.05
Immune responses to an oral typhoid vaccine strain that is modified to constitutively express Vi capsular polysaccharide. J Infect Dis (2004) 1.04
The vaccinia virus G1L putative metalloproteinase is essential for viral replication in vivo. J Virol (2004) 1.04
M.SpyI, a DNA methyltransferase encoded on a mefA chimeric element, modifies the genome of Streptococcus pyogenes. J Bacteriol (2006) 1.04
Biochemical analysis of a common human polymorphism associated with age-related macular degeneration. Biochemistry (2007) 1.03
Vaccinia virus p37 interacts with host proteins associated with LE-derived transport vesicle biogenesis. Virol J (2009) 1.03
Efficacy of ST-246 versus lethal poxvirus challenge in immunodeficient mice. Proc Natl Acad Sci U S A (2009) 1.03
In vivo lysogenic conversion of Tox(-) Streptococcus pyogenes to Tox(+) with Lysogenic Streptococci or free phage. Infect Immun (2003) 1.02
The vaccinia virus F13L YPPL motif is required for efficient release of extracellular enveloped virus. J Virol (2007) 1.02
A novel inhibitor of dengue virus replication that targets the capsid protein. Antimicrob Agents Chemother (2012) 1.02
Conditional expression of vaccinia virus genes in mammalian cell lines expressing the tetracycline repressor. J Virol Methods (2004) 1.01
A conditional-lethal vaccinia virus mutant demonstrates that the I7L gene product is required for virion morphogenesis. Virol J (2005) 1.01
PlyPH, a bacteriolytic enzyme with a broad pH range of activity and lytic action against Bacillus anthracis. J Bacteriol (2006) 1.01
Vaccinia virus proteolysis--a review. Rev Med Virol (2006) 1.00
Comprehensive analysis of antibody responses to streptococcal and tissue antigens in patients with acute rheumatic fever. Int Immunol (2008) 0.99
Immune responses to the smallpox vaccine given in combination with ST-246, a small-molecule inhibitor of poxvirus dissemination. Vaccine (2007) 0.98
Characterization of a unique glycosylated anchor endopeptidase that cleaves the LPXTG sequence motif of cell surface proteins of Gram-positive bacteria. J Biol Chem (2002) 0.96
A structural basis for the allosteric regulation of non-hydrolysing UDP-GlcNAc 2-epimerases. EMBO Rep (2008) 0.95
Evaluation of Lassa antiviral compound ST-193 in a guinea pig model. Antiviral Res (2011) 0.94
Chlamydial development is blocked in host cells transfected with Chlamydophila caviae incA. BMC Microbiol (2004) 0.94
Use of a bacteriophage lysin to identify a novel target for antimicrobial development. PLoS One (2013) 0.93
Identifying active phage lysins through functional viral metagenomics. Appl Environ Microbiol (2010) 0.93
Genomic sequence of C1, the first streptococcal phage. J Bacteriol (2003) 0.93
Progressive vaccinia: case description and laboratory-guided therapy with vaccinia immune globulin, ST-246, and CMX001. J Infect Dis (2012) 0.93
Rapid DNA library construction for functional genomic and metagenomic screening. Appl Environ Microbiol (2007) 0.92
A genetic screen to identify bacteriophage lysins. Methods Mol Biol (2009) 0.92
Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects. Antimicrob Agents Chemother (2010) 0.91
Novel benzoxazole inhibitor of dengue virus replication that targets the NS3 helicase. Antimicrob Agents Chemother (2013) 0.91
Characterization of the most prevalent colonization factor antigens present in Chilean clinical enterotoxigenic Escherichia coli strains using a new multiplex polymerase chain reaction. Diagn Microbiol Infect Dis (2009) 0.89
A stable phage lysin (Cpl-1) dimer with increased antipneumococcal activity and decreased plasma clearance. Int J Antimicrob Agents (2011) 0.88